Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease

NCT00239564 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Parkinson's Disease

Interventions

DRUG: IPX054 100 mg
DRUG: IPX054 150 mg
DRUG: IPX054 200 mg
DRUG: IPX054 250 mg
DRUG: IPX054 300 mg

Sponsor

Impax Laboratories, LLC